Profile data is unavailable for this security.
About the company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
- Revenue in USD (TTM)61.52m
- Net income in USD-103.46m
- Incorporated2016
- Employees183.00
- LocationEntrada Therapeutics IncOne Design Center Place, Suite 17-500BOSTON 02210United StatesUSA
- Phone+1 (857) 305-1825
- Fax+1 (302) 655-5049
- Websitehttps://www.entradatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absci Corp | 2.82m | -114.60m | 383.45m | 156.00 | -- | 1.82 | -- | 136.22 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Climb Bio Inc | 0.00 | -50.75m | 386.61m | 17.00 | -- | 2.18 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 402.24m | 16.00 | -- | 4.78 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 403.01m | 42.00 | -- | -- | -- | 23.03 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Regenxbio Inc | 161.32m | -177.92m | 404.48m | 353.00 | -- | 2.51 | -- | 2.51 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 404.51m | 226.00 | -- | 1.27 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 410.20m | 104.00 | 21.15 | 5.79 | 19.35 | 3.29 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 414.75m | 129.00 | -- | 2.09 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 415.83m | 183.00 | -- | 1.22 | -- | 6.76 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 417.00m | 51.00 | -- | 1.56 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 421.68m | 73.00 | -- | 2.31 | -- | 11.34 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| PepGen Inc | 0.00 | -93.56m | 442.74m | 81.00 | -- | 2.71 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 444.22m | 27.00 | -- | 8.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 447.98m | 30.00 | -- | 3.65 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Entrada Therapeutics Inc's reporting currency: US Dollar USD
32.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 20 Nov 2025 | 5.07m | 13.27% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.78m | 4.67% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.46m | 3.83% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 954.42k | 2.50% |
| Millennium Management LLCas of 30 Sep 2025 | 836.61k | 2.19% |
| Geode Capital Management LLCas of 30 Sep 2025 | 645.12k | 1.69% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 594.30k | 1.56% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 498.62k | 1.31% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 372.27k | 0.97% |
| Royce & Associates LPas of 30 Sep 2025 | 345.51k | 0.90% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
